Paper Details

  1. Home
  2. Paper Details

Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer.

Author: GeldofA A, RaoB R, de VoogtH J, van der WiltC L

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A combination of Anandron and estradiol was effective in treating hormone-dependent prostatic adenocarcinoma in rats. The combination significantly retarded tumor growth.
Paper Details　
Original Abstract of the Article :
Treatment effects of RU 23908 antiandrogen (Anandron) and estrogen in low doses on hormone-dependent rat prostatic adenocarcinoma (R3327-H) were investigated. Tumor-bearing Copenhagen rats were treated for 6 weeks with 8 micrograms Anandron and 1 microgram estradiol-17 beta every two days. Reduction...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/pros.2990130108

データ提供：米国国立医学図書館（NLM）

A New Approach to Prostate Cancer Treatment: A Combination Therapy

Prostate cancer, like a stubborn desert weed, can be difficult to eradicate. This study explores the potential benefits of a combination therapy involving low doses of Anandron (RU 23908 antiandrogen) and estrogen in treating hormone-dependent prostate cancer.

Researchers investigated the effects of this combination therapy on tumor growth in a rat model of prostate cancer. They found that the combination significantly retarded tumor growth, comparable to the effects of castration, while minimizing potential side effects. This suggests that this combination therapy could be a promising alternative for treating hormone-dependent prostate cancer.

A Novel Approach to Prostate Cancer Treatment: Minimizing Side Effects

This study underscores the potential benefits of a combination therapy involving Anandron and estrogen in treating hormone-dependent prostate cancer. The combination's ability to retard tumor growth while minimizing side effects could make it a valuable option for patients.

Navigating the Desert of Prostate Cancer: Exploring Treatment Options and Risks

For individuals facing prostate cancer, it is crucial to discuss treatment options with a healthcare professional. This study highlights the potential benefits of a combination therapy involving Anandron and estrogen, but it's important to weigh the potential risks and benefits carefully.

Dr. Camel's Conclusion

This research, like a desert prospector discovering a new vein of gold, sheds light on the potential benefits of a combination therapy involving Anandron and estrogen in treating prostate cancer. The study's findings offer hope for a more effective and less invasive approach to managing this challenging condition.

Date :
  1. Date Completed 1988-10-26
  2. Date Revised 2019-09-12
Further Info :

Pubmed ID

3420036

DOI: Digital Object Identifier

10.1002/pros.2990130108

Related Literature

Article Analysis
・Side Effects of nilutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.